[en] Ceramide-activated NAD(P)H oxidase has been reported to participate in homocysteine (Hcys)-induced abnormal metabolism of the extracellular matrix (ECM) in rat glomerular mesangial cells. However, it remains unknown whether this ceramide-redox signaling pathway contributes to glomerular injury induced by hyperhomocysteinemia (hHcys) in vivo. The present study was designed to address this question, defining the role of ceramide and activated NAD(P)H oxidase in the development of hHcys-induced glomerular injury. Uninephrectomized Sprague-Dawley rats were fed a folate-free diet for 8 weeks to produce hHcys and the de novo ceramide synthesis inhibitor myriocin or the NAD(P)H oxidase inhibitor apocynin was administrated. Rats with folate-free diet significantly increased plasma Hcys levels, renal ceramide levels, and NAD(P)H oxidase activity accompanied by marked glomerular injury. Treatment of rats with myriocin significantly reduced ceramide levels and improved glomerular injury, as shown by decreased urinary albumin excretion and reduced glomerular damage index. ECM components changed towards to normal levels with decreased tissue inhibitor of metalloproteinase-1 and increased matrix metalloproteinase-1 activity. NAD(P)H oxidase activity and Rac GTPase activity were reduced by 69 and 66%, respectively. In rats treated with apocynin, similar beneficial effects in protecting glomeruli from hHcys-induced injury were observed. These results support the view that de novo ceramide production is involved in Hcys-induced NAD(P)H oxidase activity in the kidney of hHcys rats and indicate the important role of ceramide-mediated redox signaling in hHcys-induced glomerular injury in rats.
Disciplines :
Pharmacy, pharmacology & toxicology
Author, co-author :
Yi, F.; Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
Zhang, A. Y.; Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
Li, N.; Department of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia, USA
Muh, R. W.; Department of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia, USA
Fillet, Marianne ; Université de Liège - ULiège > Département de pharmacie > Analyse des médicaments
Renert, A.-F.; Université de Liège - ULiège
Li, P.-L.; Department of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia, USA
Language :
English
Title :
Inhibition of ceramide-redox signaling pathway blocks glomerular injury in hyperhomocysteinemic rats.
Publication date :
2006
Journal title :
Kidney International
ISSN :
0085-2538
eISSN :
1523-1755
Publisher :
Nature Publishing Group, New York, United States - New York
Volume :
70
Issue :
1
Pages :
88-96
Peer reviewed :
Peer Reviewed verified by ORBi
Funders :
F.R.S.-FNRS - Fonds de la Recherche Scientifique [BE]
Bostom AG, Lathrop L. Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 1997; 52: 10-20.
Dennis VW, Nurko S, Robinson K. Hyperhomocysteinemia: detection, risk assessment, and treatment. Curr Opin Nephrol Hypertens 1997; 6: 483-488.
Dennis VW, Robinson K. Homocysteinemia and vascular disease in end-stage renal in patients with chronic renal failure. Kidney Int 1997; 52: 495-502.
Perna AF, Ingrosso D, Castaldo P et al. Homocysteine, a new crucial element in the pathogenesis of uremic cardiovascular complications. Miner Electrolyte Metab 1999; 25: 95-99.
Bostom AG, Shemin D, Lapane KL et al. Hyperhomocystinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control study. Atherosclerosis 1995; 114: 93-103.
Ducloux D, Motte G, Challier B et al. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study. J Am Soc Nephrol 2000; 11: 134-137.
Li N, Chen YF, Zou AP. Implications of hyperhomocysteinemia in glomerular sclerosis in hypertension. Hypertension 2002; 39: 443-448.
McCully KS. The Homocysteine Revolution: Medicine for the New Millennium. Keats Publishing: New Canaan, CT, 1997.
McCully KS. Chemical pathology of homocysteine. I atherogenesis. II Carcinogenesis and homocysteine thiolacton metabolism. III Cellular function and aging. Ann Clin Lab Sci 1993; 23: 477-493.
McCully KS. Atherosclerosis, serum cholesterol and the homocysteine theory: a study of 194 consecutive autopsies. Am J Med Sci 1990; 299: 217-221.
De Groote MA, Testerman T, Xu Y et al. Homocysteine antagonism of nitric oxide-related cytostasis in Salmonella typhimurium. Science 1996; 272: 414-417.
Harker LA, Ross R, Slichter SJ, Scott CR. Homocystine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976; 58: 731-741.
Kanani PM, Sinkey CA, Browning RL et al. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e) inemia in humans. Circulation 1999; 100: 1161-1168.
Yang ZZ, Zou AP. Homocysteine enhances TIMP-1 expression and cell proliferation associated with NADH oxidase in rat mesangial cells. Kidney Int 2003; 63: 1012-1020.
Yi F, Zhang AY, Janscha J et al. Homocysteine activate NADH/NADPH oxidase through ceramide-stimulated rac activity in rat mesangial cells. Kidney Int 2004; 66: 1977-1987.
Yin T, Sandhu G, Wolfgang CD et al. Tissue-specific pattern of stress kinase activation in ischemic/reperfused heart and kidney. J Biol Chem 1997; 272: 19943-19950.
Kaushal GP, Singh AB, Shah SV. Identification of caspase (ICE-like proteases) gene family in rat kidney and altered expression in ischemia/reperfusion injury. Am J Physiol 1998; 274: F587-F595.
Ueda N, Kaushal GP, Shah SV. Apoptotic mechanisms in acute renal failure. Am J Med 2000; 108: 403-415.
Zhang DX, Zou AP, Li PL. Ceramide-induced activation of NADPH oxidase and endothelial dysfunction in small coronary arteries. Am J Physiol Heart Circ Physiol 2003; 284: H605-H612.
Duthie SJ, Grant G, Narayanan S. Increased uracil misincorporation in lymphocytes from folate-deficient rats. Br J Cancer 2000; 83: 1532-1537.
Miller JW, Nadeau MR, Smith J et al. Folate-deficiency-induced homocysteinaemia in rats: disruption of S-adenosylmethionine's co-ordinate regulation of homocysteine metabolism. Biochem J 1994; 298(Part 2): 415-419.
Bonaventura D, Tirapelli CR, Haddad R et al. Chronic methionine load-induced hyperhomocysteinemia enhances rat carotid responsiveness for angiotensin II. Pharmacology 2004; 70: 91-99.
Dbaibo GS, El-Assaad W, Krikorian A et al. Ceramide generation by two distinct pathways in tumor necrosis factor alpha-induced cell death. FEBS Lett 2001; 503: 7-12.
Tummalapalli CM, Tyagi SC. Responses of vascular smooth muscle cell to extracellular matrix degradation. J Cell Biochem 1999; 75: 515-527.
Wallner EI, Yang Q, Peterson DR et al. Relevance of extracellular matrix, its receptors, and cell adhesion molecules in mammalian nephrogenesis. Am J Physiol Renal Physiol 1998; 275: F467-F477.
Schaefer L, Han X, August C et al. Differential regulation of glomerular gelatinase B (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in obese Zucker rats. Diabetologia 1997; 40: 1035-1043.
Torres L, Garcia-Trevijiano ER, Rodriguez JA et al. Induction of TIMP-1 expression in rat hepatic stellate cells and hepatocytes: a new role for homocysteine in liver fibrosis. Biochim Biophys Acta 1999; 1455: 12-22.
Hubchak SC, Runyan CE, Kreisberg JI, Schnaper HW. Cytoskeletal rearrangement and signal transduction in TGF-beta1-stimulated mesangial cell collagen accumulation. J Am Soc Nephrol 2003; 14: 1969-1980.
Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995; 15: 551-561.
Coroneos E, Martinez M, McKenna S, Kester M. Differential regulation of sphingomyelinase and ceramidase activities by growth factors and cytokines. J Biol Chem 1995; 270: 23305-23309.
Hojjati MR, Li Z, Zhou H et al. Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice. J Biol Chem 2005; 280: 10284-10289.
Park TS, Panek RL, Mueller SB et al. Inhibition of sphingomyelin synthesis reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 2005; 110: 34665-34671.
Landmesser S, Dikalov SR, Price L et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003; 111: 1201-1209.
Cai H, Griendling KK, Harrison DG. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci 2003; 24: 471-478.
Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arteriosder Thromb Vasc Biol 2000; 20: 2175-2183.
Takeya RN, Ueno K, Kami M et al. Novel human homologues of p47phox and p67phox participate in activation of superoxide-producing NADPH oxidases. J Biol Chem 2003; 278: 25234-25246.
Brandes RP, Kreuzer J. Vascular NADPH oxidases: molecular mechanisms of activation. Cardiovasc Res 2005; 65: 16-27.
Geiszt M, Kopp JB, Varnai P, Leto TL. Identification of renox, an NAD(P)H oxidase in kidney. Proc Natl Acad Sci USA 2000; 97: 8010-8014.
Bokoch GM, Diebold BA. Current molecular models for NADPH oxidase regulation by Rac GTPase. Blood 2002; 100: 2692-2696.
Abo A, Pick E, Hall A et al. Activation of the NADPH oxidase involves the small GTP-binding protein p21rac1. Nature 1991; 353: 668-670.
Chen YF, Li PL, Zou AP. Effect of hyperhomocysteinemia on plasma or tissue adenosine levels and renal function. Circulation 2002; 106: 1275-1281.
Fillet M, Van Heugen JC, Servais AC et al. Separation, identification and quantitation of ceramides in human cancer cells by liquid chromatography- electrospray ionisation tandem mass spectrometry. J Chromatogr A 2002; 949: 225-233.
